Physician profile
Amy S Doss
NPI 1245640085
$1,340.66
in general payments reported to CMS, 2019-2025
11 companies · $449 in 2025
The $449 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $91.32 · 2022: $64.87 · 2023: $520 · 2024: $216 · 2025: $449.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,184.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,184.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $397.14 | 2023-2024 | Ingrezza |
| Ucb, INC. | $267.18 | 2024-2025 | Nayzilam, Briviact |
| Axsome Therapeutics, INC. | $125.00 | 2025 | Auvelity |
| Abbvie INC. | $123.25 | 2025 | |
| Acadia Pharmaceuticals INC | $91.32 | 2021 | |
| Sumitomo Pharma America, INC. | $91.28 | 2023 | Gemtesa |
| Lundbeck LLC | $79.06 | 2024 | Vyepti |
| Novo Nordisk INC | $64.87 | 2022 | |
| Gilead Sciences, INC. | $47.27 | 2023 | Epclusa |
| Teva Pharmaceuticals USA, INC. | $38.31 | 2024 | Austedo Xr |
| Hartmann USA, INC. | $15.98 | 2025 | Zetuvit Plus 10x10 P10 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Doss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.